| 包装 | 价格(元) |
| 10mM (in 1mL DMSO) | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 250mg | 电议 |
Cell lines | 1116 strains including 659 Gram-negative bacteria, 271 Gram-positive organisms, 96 strains of more rarely isolated species and 90 strictly anaerobic bacteria. |
Preparation method | The solubility of this compound in DMSO is >19.2mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
Reacting condition | 0-25 mg/l |
Applications | In 659 Gram-negative bacteria, Meropenem exhibited the widest spectrum of activity against these listed species and inhibited all but nine strains (MICs≥16mg/l). In 271 Gram-positive organisms tested, only two methicillin-resistant staphylococci and five Enterococcus faecium strains had meropenem MICs of ≥16mg/l. In 90 strains of strictly anaerobic organisms, Meropenem was quite active against these bacteria with an overall MIC90 of 1 mg/1. |
Animal models | Septic rat model of Klebsiella pneumoniae |
Dosage form | 30 mg/kg and an equivalent dose of the drug-loaded nanoparticle dispersion; single intraperitoneal injection |
Application | In septic rat model of Klebsiella pneumoniae, treatment with free meropenem exhibited 30% mortality, which was not statistically significant, as compared to the control untreated rats (50% mortality). However, all rats treated with the drug-loaded nanoparticle dispersions survived during the 48 h, suggesting a significant improvement of survival rate. Infected animals treated with free meropenem showed no significant reduction of blood bacterial count, while the drug-loaded nanoparticles significantly reduced blood bacterial counts. |
Other notes | Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
| 产品描述 | Meropenem is an ultra-broad-spectrum injectable β-lactam antibiotic used to treat a wide variety of infections. Meropenem has been shown to inhibit penicillinase-negative, -positive and methicillin-susceptible staphylococci [1]. In vitro: The meropenem MICs for penicillin-resistant Streptococcus pneumoniae were higher than for the penicillin-susceptible strains but the organisms remained susceptible. Clinical susceptibility in vitro to meropenem was defined by MICs of ≤ 4 mg/L, intermediate susceptibility by MICs of 8 mg/L and MICs of ≥ 16 mg/L define resistance; equivalent figures for zones of growth inhibition were ≥ 14 (susceptible), 12-13 (intermediate) and ≤ 11 (resistant) mm[1].Meropenem was 2- to 4-fold more active than imipenem against Gram-negative organisms and its spectrum of antimicrobial activity was wider than those of all other drugs tested.Meropenem inhibited all anaerobic bacteria at less than or equal to 8 mg/l and 0.25 mg/l inhibited 50% of strains. Meropenem MICs were not significantly influenced by high inocula and the drug was generally bactericidal [2].Meropenem bound most strongly to penicillin-binding protein 2 of Escherichia coli and Pseudomonas aeruginosa, and to penicillin-binding proteins 1 of Staphylococcus aureus [3].Meropenem had one identified metabolite, a β-lactam ring-opened form which is devoid of microbiological activity[4]. In vivo: In rabbits, meropenem significantly increased the plamsa total clearance of valproate to about 1.5 times compared to the control (6.09 mL/min/kg vs. 4.28 mL/min/kg). Meropenem significantly increased the urinary excretion of valproate- glucuronide in rabbits [5]. References: |
m.cnreagent.com